State Street’s Aevi Genomic Medicine Inc GNMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-17,213
| Closed | -$3K | – | 3830 |
|
|
2019
Q4 | $3K | Hold |
17,213
| – | – | ﹤0.01% | 3806 |
|
|
2019
Q3 | $3K | Hold |
17,213
| – | – | ﹤0.01% | 3805 |
|
|
2019
Q2 | $3K | Hold |
17,213
| – | – | ﹤0.01% | 3813 |
|
|
2019
Q1 | $3K | Hold |
17,213
| – | – | ﹤0.01% | 3742 |
|
|
2018
Q4 | $12K | Hold |
17,213
| – | – | ﹤0.01% | 3729 |
|
|
2018
Q3 | $21K | Sell |
17,213
-3,287
| -16% | -$3.67K | ﹤0.01% | 3735 |
|
|
2018
Q2 | $23K | Hold |
20,500
| – | – | ﹤0.01% | 3723 |
|
|
2018
Q1 | $42K | Hold |
20,500
| – | – | ﹤0.01% | 3672 |
|
|
2017
Q4 | $25K | Hold |
20,500
| – | – | ﹤0.01% | 3681 |
|
|
2017
Q3 | $26K | Hold |
20,500
| – | – | ﹤0.01% | 3708 |
|
|
2017
Q2 | $27K | Sell |
20,500
-341,975
| -94% | -$494K | ﹤0.01% | 3640 |
|
|
2017
Q1 | $674K | Buy |
362,475
+16,777
| +5% | +$75.9K | ﹤0.01% | 3342 |
|
|
2016
Q4 | $1.79M | Buy |
345,698
+46,149
| +15% | +$243K | ﹤0.01% | 3139 |
|
|
2016
Q3 | $1.67M | Buy |
299,549
+6,397
| +2% | +$36.5K | ﹤0.01% | 3041 |
|
|
2016
Q2 | $1.63M | Buy |
293,152
+36,152
| +14% | +$190K | ﹤0.01% | 3106 |
|
|
2016
Q1 | $1.13M | Buy |
257,000
+35,496
| +16% | +$146K | ﹤0.01% | 3189 |
|
|
2015
Q4 | $1.34M | Buy |
221,504
+58,465
| +36% | +$397K | ﹤0.01% | 3134 |
|
|
2015
Q3 | $1.28M | Buy |
163,039
+50,966
| +45% | +$395K | ﹤0.01% | 3155 |
|
|
2015
Q2 | $688K | Buy |
112,073
+92,073
| +460% | +$713K | ﹤0.01% | 3314 |
|
|
2015
Q1 | $160K | Buy |
+20,000
| New | +$151K | ﹤0.01% | 3509 |
|
State Street's GNMX Position: Q1 2020 in Review
State Street sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2020, closing a stake of 17,213 shares — an estimated $3K sold.
State Street first reported a position in GNMX in Q1 2015 and held it in 20 quarters. The position peaked at $1.79M in Q4 2016. 2 funds tracked by Wall St. Rank hold GNMX as of Q1 2020.
- State Street reported no remaining Aevi Genomic Medicine Inc position as of Q1 2020 after selling out during the quarter.
- State Street sold 17,213 Aevi Genomic Medicine Inc shares in Q1 2020, an estimated $3K.
- State Street first reported a position in Aevi Genomic Medicine Inc in Q1 2015 and held it in 20 quarters.
- State Street's Aevi Genomic Medicine Inc position peaked at $1.79M in Q4 2016.
- 2 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2020.
Based on State Street's 13F filing for Q1 2020, filed 11 May 2020.